covid
Buscar en
Porto Biomedical Journal
Toda la web
Inicio Porto Biomedical Journal Imaging features of brain metastases from testicular cancer
Información de la revista
Vol. 2. Núm. 5.
Páginas 223-224 (septiembre - octubre 2017)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 2. Núm. 5.
Páginas 223-224 (septiembre - octubre 2017)
PS191
Open Access
Imaging features of brain metastases from testicular cancer
Visitas
6082
Ana Filipa Pinto1,
Autor para correspondencia
anafilipapinto95@gmail.com

Corresponding author.
, Susana Maria Silva2,3, Eduarda Carneiro4, Diana Ferreira4, Joaquina Maurício5, Mavilde Arantes2,3,4
1 Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal
2 Unit of Anatomy, Department of Biomedicine, Faculty of Medicine of the University of Porto, 4200-319 Porto, Portugal
3 Center for Health Technology and Services Research (CINTESIS), 4200-450 Porto, Portugal
4 Division of Neuroradiology, Radiology Service, Portuguese Institute of Oncology, Porto, Portugal
5 Medical Oncology Service, Portuguese Institute of Oncology, Porto, Portugal
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo

Aim: Our study evaluated the incidence, imaging characteristics, and prognosis of brain metastases originating from primary testicular tumors.

Introduction: Approximately 95% of testicular tumors are testicular germ cell tumors (TGCT).1 Sertoli cell tumors are rare non-germ cell origin tumors and account for less than 1% of testicular cancer.2 Brain metastases from germ cell tumors are very uncommon, occurring in less than 2–3% of patients.3 In testicular cell cancer, it is estimated that the incidence of brain metastases is 1–2% in all TGCT, whereas in advanced stages of TGCT the incidence rises to about 10–15% 4–9

Methods: Case records of testicular tumors patients within the IPO Porto data base from 2006 to 2015 were reviewed to identify patients with testicular tumors and evidence of brain metastases.

Results: 368 patients with testicular tumors were identified, with only four having evidence of brain metastases. Histopathological evaluation reveled that one of the patients had a non-germ cell tumor, a Sertoli cell tumor, while others had mixed germ cell tumors. Half of them had only a single right frontoparietal lesion (21mm) or right occipital (42mm), both were heterogeneous in T1WI and T2WI, and with intense and heterogeneous enhancement with gadolinium. The other two patients had multiple lesions. One of them had left frontoparietal (2.2mm, hyperintense in T1) and right occipital (1.8mm, hypointense in T1) lesions, both heterogeneous and predominantly hypointense in T2 and T1WI with no enhancement. The other had right temporal (5mm) and left occipital (11mm) lesions, both isointense in T1W1 and T2WI with intense and homogeneous enhancement. There was no diffusion restriction in all three cases and all four cases were hypointense in T2*.

Conclusion: Although the imaging features of brain metastases differ in some aspects, they all have a hemorrhagic component and a very low survival rate after diagnosis.

References
[1]
E. Huyghe, T. Matsuda, P. Thonneay.
Increasing incidence of testicular cancer worldwide: a review.
[2]
I.A. Sesterhenn, J. Cheville, P.J. Woodward, et al.
Sex cord/gonadal stromal tumours.
Pathology and genetics of tumours of the urinary system and male genital organs, pp. 250-255
[3]
S. Raj, C. Parkinson, M. Williams, D. Mazhar.
Management of brain metastases from germ cell tumors: do we know what we are doing?.
Future Oncol, 4 (2008), pp. 1-4
[4]
V. Raina, S.P. Singh, N. Kamble, et al.
Brain metastasis as the site of relapse in germ cell tumor of testis.
Cancer, 72 (1993), pp. 2182-2185
[5]
M. Bower, E.S. Newlands, L. Holden, G.J. Rustin, R.H. Begent.
Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.
Ann Oncol, 8 (1997), pp. 477-483
[6]
C. Bokemeyer, P. Nowak, A. Haupt, et al.
Treatment of brain metastases in patients with testicular cancer.
J Clin Oncol, 15 (1997), pp. 1449-1454
[7]
S.D. Fossa, C. Bokemeyer, A. Gerl, et al.
Treatment outcome of patients with brain metastases from malignant germ cell tumors.
Cancer, 85 (1999), pp. 988-997
[8]
S.D. Williams, L.H. Einhorn.
Brain metastases in disseminated germinal neoplasms: incidence and clinical course.
Cancer, 44 (1979), pp. 1514-1516
[9]
S.B. Kaye, K.D. Bagshawe, T.J. McElwain, M.J. Peckham.
Brain metastases in malignant teratoma: a review of four years’ experience and an assessment of the role of tumour markers.
Br J Cancer, 39 (1979), pp. 217-223
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos